Viridian Therapeutics Inc [VRDN] stock is trading at $13.81, up 4.15%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The VRDN shares have gain 5.99% over the last week, with a monthly amount drifted -17.26%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, BTIG Research started tracking the stock with Buy rating on June 14, 2023, and set its price target to $46. On May 30, 2023, RBC Capital Mkts initiated with a Outperform rating and assigned a price target of $44 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $46 on April 17, 2023. Stifel initiated its recommendation with a Buy and recommended $49 as its price target on March 30, 2023. Needham started tracking with a Buy rating for this stock on December 19, 2022, and assigned it a price target of $45. In a note dated December 19, 2022, Cowen initiated an Outperform rating and provided a target price of $45 on this stock.
Viridian Therapeutics Inc [VRDN] stock has fluctuated between $10.93 and $28.99 over the past year. Currently, Wall Street analysts expect the stock to reach $44.4 within the next 12 months. Viridian Therapeutics Inc [NASDAQ: VRDN] shares were valued at $13.81 at the most recent close of the market. An investor can expect a potential return of 221.51% based on the average VRDN price forecast.
Analyzing the VRDN fundamentals
Viridian Therapeutics Inc [NASDAQ:VRDN] reported sales of 0.31M for the trailing twelve months, which represents a drop of -31.43%. Gross Profit Margin for this corporation currently stands at -3.21% with Operating Profit Margin at -810.35%, Pretax Profit Margin comes in at -757.11%, and Net Profit Margin reading is -756.78%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is -0.68 and Total Capital is -0.55. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.28 points at the first support level, and at 12.75 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.37, and for the 2nd resistance point, it is at 14.93.
Viridian Therapeutics Inc [VRDN] reported earnings per share of -$1.35 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1/share, meaning a difference of -$0.35 and a surprise factor of -35.00%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$1.09 per share as compared to estimates of -$1.27 per share, a difference of $0.18 representing a surprise of 14.20%.
Ratios To Look Out For
For context, Viridian Therapeutics Inc’s Current Ratio is 18.26. Further, the Quick Ratio stands at 18.26, while the Cash Ratio is 3.86. Considering the valuation of this stock, the price to sales ratio is 2843.08, the price to book ratio is 3.17.
Transactions by insiders
Recent insider trading involved Fairmount Funds Management LLC, Director, that happened on Jan 22 ’24 when 0.48 million shares were purchased. Chief Legal Officer, Meisner Lara completed a deal on Jun 16 ’23 to sell 27.0 shares. Meanwhile, Chief Legal Officer Meisner Lara sold 2269.0 shares on Jun 15 ’23.
